Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

9536 ARTÍCULOS , VIENDO DEL 1636 AL 1650

GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Kim KY, Shin KY, Chang KA.

Cells. 2023 May 4;12(9):1309. doi: 10.3390/cells12091309.

Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer's Disease: Systematic Review and Meta-Analysis

Zabala-Findlay A, Penny LK, Lofthouse RA, Porter AJ, Palliyil S, Harrington CR, Wischik CM, Arastoo M.

Cells. 2023 Apr 18;12(8):1184. doi: 10.3390/cells12081184.

Blood biomarkers for Alzheimer's disease in clinical practice and trials

Hansson O, Blennow K, Zetterberg H, Dage J.

Nat Aging. 2023 May;3(5):506-519. doi: 10.1038/s43587-023-00403-3. Epub 2023 May 18.

Detection and treatment of Alzheimer's disease in its preclinical stage

Rafii MS, Aisen PS.

Nat Aging. 2023 May;3(5):520-531. doi: 10.1038/s43587-023-00410-4. Epub 2023 May 18.

Co-twin design in brain imaging-review on biomarkers of Alzheimer's disease

Varjonen A, Schwarz C, Vuoksimaa E.

Cereb Cortex. 2023 Jul 5;33(14):9054-9066. doi: 10.1093/cercor/bhad181.

CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease

Papaliagkas V, Kalinderi K, Vareltzis P, Moraitou D, Papamitsou T, Chatzidimitriou M.

Int J Mol Sci. 2023 May 19;24(10):8976. doi: 10.3390/ijms24108976.

Comparing three neuropsychological subgrouping approaches in subjective and mild cognitive impairment from a naturalistic multicenter study

Rennie A, Ekman U, Wallert J, Muehlboeck JS, Eriksdotter M, Wahlund LO, Ferreira D, Westman E.

Neurobiol Aging. 2023 Sep;129:41-49. doi: 10.1016/j.neurobiolaging.2023.04.008. Epub 2023 Apr 25.

Blood and CSF chemokines in Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis

Zhou F, Sun Y, Xie X, Zhao Y.

Alzheimers Res Ther. 2023 Jun 8;15(1):107. doi: 10.1186/s13195-023-01254-1.

Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape

Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O'Bryant S, Shaw LM, Cho M, Batrla R, Vergallo A, Blennow K, Dage J, Schindler SE.

Neuron. 2023 Sep 20;111(18):2781-2799. doi: 10.1016/j.neuron.2023.05.017. Epub 2023 Jun 8.

Association between lipocalin-2 and mild cognitive impairment or dementia: A systematic review and meta-analysis of population-based evidence

Li X, Wang X, Guo L, Wu K, Wang L, Rao L, Liu X, Kang C, Jiang B, Li Q, Li H, He F, Lu C.

Ageing Res Rev. 2023 Aug;89:101984. doi: 10.1016/j.arr.2023.101984. Epub 2023 Jun 15.

Predicting cognitive decline in older people by structural and molecular imaging

Teipel S, Tang Y, Boccardi M.

Curr Opin Neurol. 2023 Aug 1;36(4):253-263. doi: 10.1097/WCO.0000000000001172. Epub 2023 Jun 19.

Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials

Rahman-Filipiak A, Bolton C, Grill JD, Rostamzadeh A, Chin N, Heidebrink J, Getz S, Fowler NR, Rosen A, Lingler J, Wijsman E, Clark L; Advisory Group on Risk Evidence Education in Dementia (AGREED).

Alzheimers Dement. 2023 Sep;19(9):4270-4275. doi: 10.1002/alz.13380. Epub 2023 Jul 14.

PET Radiomics of White Matter, Can Be Employed as a Biomarker to Identify the Progression of Mild Cognitive Impairment to Alzheimer's Disease

Chen F.

Acad Radiol. 2023 Sep;30(9):1885-1886. doi: 10.1016/j.acra.2023.06.020. Epub 2023 Jul 17.

The performance of plasma phosphorylated tau231 in detecting Alzheimer's disease: A systematic review with meta-analysis

Xu C, Zhao L, Dong C.

Eur J Neurosci. 2023 Aug;58(4):3132-3149. doi: 10.1111/ejn.16085. Epub 2023 Jul 27.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias